ATP128
Advanced Microsatellite-Stable Colorectal Cancer (MSS-CRC)
Phase 1bActive
Key Facts
Indication
Advanced Microsatellite-Stable Colorectal Cancer (MSS-CRC)
Phase
Phase 1b
Status
Active
Company
About AMAL Therapeutics
AMAL Therapeutics is a private, clinical-stage biotechnology company pioneering a novel class of therapeutic vaccines. Its proprietary KISIMA® platform combines multiple functional units into a single recombinant protein to generate a powerful, targeted immune activation against cancer cells and pathogens. The company's lead asset, ATP128, is a neoantigen-based therapeutic cancer vaccine that has entered clinical development. AMAL aims to address significant unmet medical needs in oncology by harnessing the immune system to treat established diseases, moving beyond traditional prophylactic vaccines.
View full company profile